A retrospective cohort study assessing rationale for use of Ocrelizumab in relapsing MS (RMS) and primary progressive multiple sclerosis (PPMS) patients
Latest Information Update: 26 Mar 2021
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 26 Mar 2021 New trial record
- 27 Feb 2021 Results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2021.